astrazeneca’s immunotherapy imjudo (tremelimumab) wins fda approval for liver cancer
Published 1 year ago • 2.6K plays • Length 0:42Download video MP4
Download video MP3
Similar videos
-
0:40
imjudo injection, tremelimumab, astrazeneca, hepatocellular carcinoma, new drug approval, #shorts
-
1:00
astrazeneca’s blockbuster drug scores major win in bladder cancer | n18s | cnbc tv18
-
1:48
imjudo (tremelimumab-actl) injection- hepatocellular carcinoma
-
3:49
update from esmo 2024: immunotherapy (io) for hcc
-
0:21
astrazeneca pharma india limited is set to launch tremelimumab imjudo in india in october 2024
-
3:01
fda d.i.s.c.o. burst edition: fda approval of imjudo (tremelimumab) in combination with imfinzi (...
-
28:59
evolving options for the treatment of hcc with immunotherapy and liver directed therapy (ldt)
-
3:24
'tumors just vanished': cancer patients now in remission after drug trial
-
3:55
the use of immunotherapy in hcc – efficacy and safety
-
30:59
how is immunotherapy for liver cancer changing the outlook for patients?
-
0:16
astrazeneca says cancer drug imfinzi improves survival chances in late-stage trial|#shorts
-
2:43
new immunotherapies bring hope to patients with rare liver cancers
-
1:23
improving upon immunotherapy advances in hcc
-
2:18
dr. ulahannan on immunotherapy in hepatocellular carcinoma
-
2:25
imfinzi (durvalumab) plus bevacizumab met endpoints in emerald-1 phase iii results in liver cancer
-
3:34
himalaya: does underlying liver function impact efficacy of tremelimumab plus durvalumab for hcc?
-
4:53
checkpoint inhibition in hepatocellular carcinoma
-
1:57
recent immunotherapy advances in hcc management
-
2:15
future of immunotherapy in liver cancer